Cara Therapeutic Net Worth
Cara Therapeutic Net Worth Breakdown | CARA |
Cara Therapeutic Net Worth Analysis
Cara Therapeutic's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Cara Therapeutic's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Cara Therapeutic's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Cara Therapeutic's net worth analysis. One common approach is to calculate Cara Therapeutic's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Cara Therapeutic's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Cara Therapeutic's net worth. This approach calculates the present value of Cara Therapeutic's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Cara Therapeutic's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Cara Therapeutic's net worth. This involves comparing Cara Therapeutic's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Cara Therapeutic's net worth relative to its peers.
Enterprise Value |
|
To determine if Cara Therapeutic is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Cara Therapeutic's net worth research are outlined below:
| Cara Therapeutic is way too risky over 90 days horizon | |
| Cara Therapeutic appears to be risky and price may revert if volatility continues | |
| Cara Therapeutic has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 20.97 M. Net Loss for the year was (118.51 M) with loss before overhead, payroll, taxes, and interest of (77.85 M). | |
| Cara Therapeutic currently holds about 157.51 M in cash with (92.08 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.93. | |
| Roughly 16.0% of the company shares are held by company insiders | |
| Latest headline from MacroaxisInsider: Disposition of 1642 shares by Scott Terrillion of Cara Therapeutic at 11.91 subject to Rule 16b-3 |
Cara Therapeutic uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Cara Therapeutic. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Cara Therapeutic's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of March 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Cara Therapeutic Target Price Consensus
Cara target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Cara Therapeutic's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 2 | Hold |
Most Cara analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Cara stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Cara Therapeutic, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationCara Therapeutic Target Price Projection
Cara Therapeutic's current and average target prices are 5.13 and 12.12, respectively. The current price of Cara Therapeutic is the price at which Cara Therapeutic is currently trading. On the other hand, Cara Therapeutic's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Cara Therapeutic Market Quote on 30th of January 2025
Target Price
Analyst Consensus On Cara Therapeutic Target Price
Know Cara Therapeutic's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Cara Therapeutic is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Cara Therapeutic backward and forwards among themselves. Cara Therapeutic's institutional investor refers to the entity that pools money to purchase Cara Therapeutic's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Bank Of America Corp | 2024-09-30 | 327.2 K | Two Sigma Investments Llc | 2024-09-30 | 240.9 K | Fmr Inc | 2024-09-30 | 210.3 K | State Street Corp | 2024-09-30 | 180.4 K | Adar1 Capital Management Llc | 2024-09-30 | 159.5 K | Lpl Financial Corp | 2024-09-30 | 149 K | Susquehanna International Group, Llp | 2024-09-30 | 127.6 K | Xtx Topco Ltd | 2024-09-30 | 94.7 K | Tudor Investment Corp Et Al | 2024-09-30 | 93.1 K | Vanguard Group Inc | 2024-09-30 | 2.2 M | Chescapmanager Llc | 2024-09-30 | 1.7 M |
Follow Cara Therapeutic's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 22.81 M.Market Cap |
|
Project Cara Therapeutic's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.85) | (0.89) | |
| Return On Capital Employed | (1.09) | (1.04) | |
| Return On Assets | (0.85) | (0.89) | |
| Return On Equity | (1.87) | (1.78) |
When accessing Cara Therapeutic's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Cara Therapeutic's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Cara Therapeutic's profitability and make more informed investment decisions.
Please note, the presentation of Cara Therapeutic's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Cara Therapeutic's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Cara Therapeutic's management manipulating its earnings.
Evaluate Cara Therapeutic's management efficiency
Cara Therapeutic has return on total asset (ROA) of (0.6343) % which means that it has lost $0.6343 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.8432) %, meaning that it created substantial loss on money invested by shareholders. Cara Therapeutic's management efficiency ratios could be used to measure how well Cara Therapeutic manages its routine affairs as well as how well it operates its assets and liabilities. As of January 30, 2025, Return On Tangible Assets is expected to decline to -0.89. The current year's Return On Capital Employed is expected to grow to -1.04. At present, Cara Therapeutic's Non Currrent Assets Other are projected to decrease significantly based on the last few years of reporting. The current year's Debt To Assets is expected to grow to 0.32, whereas Total Assets are forecasted to decline to about 136.4 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.95 | 0.90 | |
| Tangible Book Value Per Share | 0.95 | 0.90 | |
| Enterprise Value Over EBITDA | (4.64) | (4.41) | |
| Price Book Value Ratio | 9.73 | 9.24 | |
| Enterprise Value Multiple | (4.64) | (4.41) | |
| Price Fair Value | 9.73 | 9.24 | |
| Enterprise Value | 427 M | 405.6 M |
The strategic initiatives led by Cara Therapeutic's management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Enterprise Value Revenue 4.8319 | Revenue | Quarterly Revenue Growth (0.86) | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cara Therapeutic insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cara Therapeutic's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Cara Therapeutic insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Cara Therapeutic Corporate Filings
| 27th of January 2025 Other Reports | ViewVerify | |
8K | 21st of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
8K | 20th of December 2024 An amendment to a previously filed Form 8-K | ViewVerify |
10Q | 14th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
Cara Therapeutic Earnings Estimation Breakdown
The calculation of Cara Therapeutic's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Cara Therapeutic is estimated to be 0.0 with the future projection ranging from a low of 0.0 to a high of 0.0. Please be aware that this consensus of annual earnings estimates for Cara Therapeutic is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
0.00 Lowest | Expected EPS | 0.00 Highest |
Cara Therapeutic Earnings Projection Consensus
Suppose the current estimates of Cara Therapeutic's value are higher than the current market price of the Cara Therapeutic stock. In this case, investors may conclude that Cara Therapeutic is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Cara Therapeutic's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2024 | Current EPS (TTM) | |
| 1 | 69.82% | -0.1181 | 0.0 | -21.0 |
Cara Therapeutic Earnings per Share Projection vs Actual
Actual Earning per Share of Cara Therapeutic refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Cara Therapeutic predict the company's earnings will be in the future. The higher the earnings per share of Cara Therapeutic, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Cara Therapeutic Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Cara Therapeutic, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Cara Therapeutic should always be considered in relation to other companies to make a more educated investment decision.Cara Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Cara Therapeutic's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-11-11 | 2024-09-30 | -0.245 | -0.1181 | 0.1269 | 51 | ||
2024-08-14 | 2024-06-30 | -0.27 | -0.37 | -0.1 | 37 | ||
2024-05-13 | 2024-03-31 | -0.4 | -0.56 | -0.16 | 40 | ||
2024-03-04 | 2023-12-31 | -0.41 | -0.59 | -0.18 | 43 | ||
2023-11-13 | 2023-09-30 | -0.52 | -0.52 | 0.0 | 0 | ||
2023-08-07 | 2023-06-30 | -0.54 | -0.58 | -0.04 | 7 | ||
2023-05-15 | 2023-03-31 | -0.52 | -0.49 | 0.03 | 5 | ||
2023-03-06 | 2022-12-31 | -0.32 | -0.56 | -0.24 | 75 | ||
2022-11-07 | 2022-09-30 | -0.42 | -0.43 | -0.01 | 2 | ||
2022-08-08 | 2022-06-30 | -0.25 | -0.08 | 0.17 | 68 | ||
2022-05-09 | 2022-03-31 | -0.54 | -0.52 | 0.02 | 3 | ||
2022-03-01 | 2021-12-31 | -0.52 | -0.63 | -0.11 | 21 | ||
2021-11-08 | 2021-09-30 | -0.4 | -0.02 | 0.38 | 95 | ||
2021-08-09 | 2021-06-30 | -0.53 | -0.61 | -0.08 | 15 | ||
2021-05-10 | 2021-03-31 | -0.59 | -0.47 | 0.12 | 20 | ||
2021-02-25 | 2020-12-31 | 0.36 | 1.59 | 1.23 | 341 | ||
2020-11-09 | 2020-09-30 | -0.6 | -0.35 | 0.25 | 41 | ||
2020-08-10 | 2020-06-30 | -0.67 | -0.54 | 0.13 | 19 | ||
2020-05-11 | 2020-03-31 | -0.62 | -0.62 | 0.0 | 0 | ||
2020-02-27 | 2019-12-31 | -0.66 | -0.61 | 0.05 | 7 | ||
2019-11-05 | 2019-09-30 | -0.58 | -0.74 | -0.16 | 27 | ||
2019-08-07 | 2019-06-30 | -0.61 | -0.58 | 0.03 | 4 | ||
2019-05-07 | 2019-03-31 | -0.58 | -0.56 | 0.02 | 3 | ||
2019-03-12 | 2018-12-31 | -0.58 | -0.52 | 0.06 | 10 | ||
2018-11-06 | 2018-09-30 | -0.5 | -0.51 | -0.01 | 2 | ||
2018-08-07 | 2018-06-30 | -0.32 | -0.52 | -0.2 | 62 | ||
2018-05-09 | 2018-03-31 | -0.47 | -0.51 | -0.04 | 8 | ||
2018-03-15 | 2017-12-31 | -0.4 | -0.43 | -0.03 | 7 | ||
2017-11-02 | 2017-09-30 | -0.34 | -0.38 | -0.04 | 11 | ||
2017-08-03 | 2017-06-30 | -0.62 | -0.29 | 0.33 | 53 | ||
2017-05-04 | 2017-03-31 | -0.74 | -0.81 | -0.07 | 9 | ||
2017-03-09 | 2016-12-31 | -0.48 | -0.81 | -0.33 | 68 | ||
2016-11-03 | 2016-09-30 | -0.47 | -0.42 | 0.05 | 10 | ||
2016-08-04 | 2016-06-30 | -0.42 | -0.48 | -0.06 | 14 | ||
2016-05-05 | 2016-03-31 | -0.42 | -0.39 | 0.03 | 7 | ||
2016-03-10 | 2015-12-31 | -0.33 | -0.35 | -0.02 | 6 | ||
2015-11-09 | 2015-09-30 | -0.27 | -0.19 | 0.08 | 29 | ||
2015-08-10 | 2015-06-30 | -0.24 | -0.25 | -0.01 | 4 | ||
2015-05-12 | 2015-03-31 | -0.27 | -0.21 | 0.06 | 22 | ||
2015-03-26 | 2014-12-31 | -0.3 | -0.18 | 0.12 | 40 | ||
2014-11-10 | 2014-09-30 | -0.22 | -0.29 | -0.07 | 31 | ||
2014-08-07 | 2014-06-30 | -0.22 | -0.16 | 0.06 | 27 | ||
2014-05-12 | 2014-03-31 | -0.15 | -0.22 | -0.07 | 46 | ||
2014-03-27 | 2013-12-31 | -0.18 | -0.49 | -0.31 | 172 |
Cara Therapeutic Corporate Management
| Joana Goncalves | Chief Medical Officer | Profile | |
| Beth Weinberg | VP QA | Profile | |
| Joana MD | Chief Officer | Profile | |
| Eric Vandal | Senior Commercial | Profile | |
| Frdrique Menzaghi | Chief RD | Profile | |
| Iris Francesconi | Chief Relations | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cara Therapeutic. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Cara Stock refer to our How to Trade Cara Stock guide.You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cara Therapeutic. If investors know Cara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cara Therapeutic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (21.00) | Revenue Per Share | Quarterly Revenue Growth (0.86) | Return On Assets | Return On Equity |
The market value of Cara Therapeutic is measured differently than its book value, which is the value of Cara that is recorded on the company's balance sheet. Investors also form their own opinion of Cara Therapeutic's value that differs from its market value or its book value, called intrinsic value, which is Cara Therapeutic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cara Therapeutic's market value can be influenced by many factors that don't directly affect Cara Therapeutic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cara Therapeutic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cara Therapeutic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cara Therapeutic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.